XML 20 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
RESEARCH AND DEVELOPMENT FUNDING ARRANGEMENTS AND OTHERS (Schedule Of Assumptions For Monoclonal Antibody Product) (Details) (Funding Arrangement [Member])
 0 Months Ended 12 Months Ended
Aug. 20, 2014
Dec. 31, 2013
Funding Arrangement [Member]
    
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]    
Risk-free interest rate 0.09%us-gaap_FairValueAssumptionsRiskFreeInterestRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [1] 0.25%us-gaap_FairValueAssumptionsRiskFreeInterestRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [1]
Expected volatility 57.76%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [2] 55.65%us-gaap_FairValueAssumptionsExpectedVolatilityRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [2]
Expected life 10 months 2 days [3] 1 year 6 months [3]
Expected dividend yield 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [4] 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
/ us-gaap_FairValueByLiabilityClassAxis
= us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember		 [4]
[1] Risk-free interest rate – based on the yields from U.S. treasury bonds with equivalent terms.
[2] Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the expected term of the embedded derivative.
[3] Expected life - the expected life of the conversion feature was based on the term of the embedded derivative.
[4] Expected dividend yield - was based on the fact that the Company has not paid dividends to ordinary shareholders in the past and does not expect to pay dividends to ordinary shareholders.